Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Barzolvolimab's Promise | Explore barzolvolimab's potential in chronic spontaneous urticaria, with a 41% complete response rate at 150 mg Q4W dose, despite setbacks in eosinophilic esophagitis trials |
Market Opportunities | Delve into the significant CSU market, with analysts projecting potential peak sales of $1 billion for barzolvolimab, despite challenges in the competitive landscape |
Financial Health | Learn about Celldex's robust financial position, with $673 million in cash and a strong Altman Z-Score of 20.23, providing runway through 2027 for continued development |
Analyst Outlook | Discover analyst consensus with a strong buy recommendation and price targets ranging from $30 to $90, suggesting significant potential upside from current levels |
Metrics to compare | CLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLDXPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.7x | −2.8x | −0.7x | |
PEG Ratio | 0.72 | 0.12 | 0.00 | |
Price/Book | 2.7x | 1.1x | 2.6x | |
Price / LTM Sales | 300.7x | 14.3x | 3.4x | |
Upside (Analyst Target) | 125.5% | 190.6% | 35.7% | |
Fair Value Upside | Unlock | 7.0% | 4.1% | Unlock |